Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
20 3월 2024 - 8:05PM
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage
biotechnology company committed to harnessing the power of
microglia for the treatment of neurodegenerative diseases, today
announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N,
as Chief Medical Officer. Dr. Kaufmann succeeds Christopher J.
Silber, M.D.
"Dr. Kaufmann brings a wealth of experience that
will be invaluable to the Vigil team,” said Ivana
Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive
Officer of Vigil. “As we further the development of both
iluzanebart and VG-3927, we will benefit from her extensive
background in neurological and rare diseases, as well as her proven
expertise in both domestic and global drug development.”
Dr. Kaufmann is an accomplished biotech
executive joining Vigil Neuroscience from Affinia Therapeutics
where she served as Chief Medical Officer leading medical,
clinical, patient advocacy and regulatory strategy. Prior to
Affinia Therapeutics, Dr. Kaufmann held the position of Senior Vice
President, Clinical Development, Translational Medicine &
Analytics at Novartis Gene Therapies where she led the company’s
global clinical development strategy including global approvals of
Zolgensma®. She has also served as Vice President, Translational
Medicine at AveXis (acquired by Novartis), and Head, Office of Rare
Diseases Research at the National Institutes of Health. Dr.
Kaufmann holds an M.S. in biostatistics from Columbia University
and an M.D. from the University of Bonn.
“I am honored and excited to join Vigil, a
company at the forefront of developing innovative treatments for
rare and common neurological diseases,” said Petra Kaufmann, M.D.,
M.S., F.A.A.N, Chief Medical Officer of Vigil. “I look forward to
leading our talented team of scientists, researchers and clinicians
as we work to execute on our clinical milestones with the goal of
advancing our pipeline and making a meaningful impact on the lives
of patients as quickly as possible.”
Notice of Issuance of Inducement Grant
Vigil also announced that as an inducement
material to Dr. Kaufmann entering into employment with Vigil, the
Company’s Board of Directors granted a non-qualified stock option
to Dr. Kaufmann to purchase 330,000 shares of the Company’s common
stock. The stock option has an exercise price per share that is
equal to $3.14, the closing price of Vigil’s common stock on the
grant date. The stock option has a ten-year term, and will vest
over a four-year period, with 25% of the option vesting on the
one-year anniversary of Dr. Kaufmann’s start date, and thereafter,
the remainder of the option vests in 36 equal monthly installments,
subject in each case to Dr. Kaufmann’s continued employment with
Vigil. The stock option was granted in accordance with Nasdaq
Listing Rule 5635(c)(4) and was made outside of the Company’s 2021
Stock Option and Incentive Plan (the “Plan”) but is subject to the
terms and conditions of the Plan.
About Vigil NeuroscienceVigil
Neuroscience is a clinical-stage biotechnology company focused on
developing treatments for both rare and common neurodegenerative
diseases by restoring the vigilance of microglia, the sentinel
immune cells of the brain. Vigil is utilizing the tools of modern
neuroscience drug development across multiple therapeutic
modalities in its efforts to develop precision-based therapies to
improve the lives of patients and their families. Iluzanebart,
Vigil’s lead clinical candidate, is a fully human monoclonal
antibody agonist targeting human triggering receptor expressed on
myeloid cells 2 (TREM2) in people with adult-onset
leukoencephalopathy with axonal spheroids and pigmented glia
(ALSP), a rare and fatal neurodegenerative disease. Vigil is also
developing VG-3927, a novel small molecule TREM2 agonist, to treat
common neurodegenerative diseases associated with microglial
dysfunction, with an initial focus on Alzheimer’s disease (AD) in
genetically defined subpopulations.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements” of Vigil Neuroscience’s
(“Vigil” or the “Company”) that are made pursuant to the safe
harbor provisions of the federal securities laws, including,
without limitation, express or implied statements regarding: the
Company’s clinical progress and milestones and the expected
therapeutic benefits of such programs; and the anticipated
contribution of the Company’s executives to its operations and
progress. Factors that could cause actual results to differ
include, but are not limited to, risks and uncertainties related to
uncertainties inherent in the development of product candidates,
including the conduct of research activities and the initiation and
completion of preclinical studies and clinical trials; whether
results from preclinical studies will be predictive of the results
of later preclinical studies and clinical trials; as well as the
risks and uncertainties identified in the Company’s filings with
the Securities and Exchange Commission (SEC), including Vigil’s
Quarterly Report on Form 10-Q for the quarter ended September 30,
2023 and any subsequent filings it may make with the SEC.
Forward-looking statements contained in this announcement are made
as of this date, and Vigil undertakes no duty to update such
information except as required under applicable law. Readers should
not rely upon the information on this page as current or accurate
after its publication date.
Internet Posting of
Information
Vigil Neuroscience routinely posts information
that may be important to investors in the 'Investors' section of
its website at https://www.vigilneuro.com. The company encourages
investors and potential investors to consult our website regularly
for important information about Vigil Neuroscience.
Investor Contact:Leah
GibsonVice President, Investor Relations & Corporate
CommunicationsVigil Neuroscience, Inc.lgibson@vigilneuro.com
Media Contact:Megan
McGrath MacDougall Advisorsmmcgrath@macdougall.bio
Vigil Neuroscience (NASDAQ:VIGL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Vigil Neuroscience (NASDAQ:VIGL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024